Ruxolitinib tablets/number of tablets in a bottle of Jekvi

Ruxolitinib tablets/Ruxolitinib (Ruxolitinib) is an oral JAK1/JAK2 inhibitor, mainly used in the targeted treatment of hematological diseases. As one of the earliest JAK inhibitors to enter clinical practice in the world, its advent has brought new treatment options to chronic myeloproliferative diseases such as myelofibrosis and polycythemia vera. In the context of limited effects of traditional drugs, the emergence of ruxolitinib has changed the management model of the disease, especially showing important value in controlling spleen volume, improving systemic symptoms, and improving patients' quality of life.

From the perspective of indications, ruxolitinib is mainly used to treat patients with intermediate- and high-risk myelofibrosis, including primary myelofibrosis, myelofibrosis secondary to polycythemia vera, and myelofibrosis secondary to essential thrombocythemia. These diseases are often accompanied by anemia, splenomegaly, bone marrow dysfunction, and severe systemic symptoms, and patients often face a greater burden during disease progression. Ruxolitinib inhibits the activity of the JAK-STAT signaling pathway, thereby blocking the transmission of inflammatory factors and abnormal cell signals, thereby alleviating symptoms and improving prognosis. At the same time, ruxolitinib has also been approved for the treatment of polycythemia vera patients who are resistant or intolerant to hydroxyurea therapy. These patients often lack effective treatment options, and the application of this drug fills this gap.

In terms of drug dosage forms and specifications, the dosage design of ruxolitinib is very flexible to meet the needs of different patient groups. Common packaging includes 14 tablets of 20mg and 60 tablets of 5mg. Doctors will adjust the starting dose and maintenance dose according to the patient's weight, blood level and disease type. The existence of different specifications not only facilitates individualized treatment, but also facilitates flexible adjustment of medication regimens in clinical practice. For patients who require long-term medication, common specification combinations can also help doctors reduce the risk of adverse reactions as much as possible while ensuring efficacy.

Reference materials:https://www.jakavi.com/